BiotechTube
InVitria

InVitria

Junction City, United States· Est.
invitria.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

InVitria is a global leader in providing chemically defined, recombinant cell culture media components and supplements, serving over 1,000 active customers across 40+ countries. Its core technology platform, ExpressTec, utilizes plant-based expression systems to produce animal-free proteins, addressing critical needs for supply chain reliability, regulatory compliance, and sustainability in biomanufacturing. The company's products are already incorporated into 30 on-market therapeutics, supporting a broad pipeline of over 300 customer clinical programs. As a private company, InVitria operates from its ISO-certified manufacturing facility in Kansas, USA, catering to the rapidly growing cell and gene therapy and biologics markets.

BiologicsCell Therapy

Technology Platform

ExpressTec plant-based recombinant protein expression system for producing animal-origin-free, chemically defined proteins like albumin and transferrin.

Funding History

2
Total raised:$25M
Series B$15M
Series A$10M

Opportunities

The rapid growth of cell and gene therapies, which require chemically defined, animal-free components, represents a massive and sustained growth driver.
Increasing regulatory and industry pressure to eliminate animal-derived materials from biomanufacturing creates a powerful substitution trend favoring InVitria's products.
The company's US-based, metric-ton scale manufacturing also addresses strong market demand for resilient and geographically diverse supply chains.

Risk Factors

Intense competition from large, well-capitalized life science tools companies and other specialized suppliers poses a constant challenge.
The business is dependent on the success of customers' therapeutic programs and the lengthy, costly process of qualifying its materials into their manufacturing processes.
Technological evolution in protein production or shifts in regulatory expectations could also impact the long-term competitiveness of its plant-based platform.

Competitive Landscape

InVitria competes in the cell culture media and supplements market against large diversified players like Thermo Fisher Scientific and Merck KGaA, as well as other specialized suppliers of recombinant proteins and defined media. Its key differentiators are its plant-based production platform, proven commercial track record in approved therapies, and a focused portfolio on high-growth, technically demanding applications like cell and gene therapy.

More companies in Biologics / Biosimilars →More companies in United States →